New 'Living Drug' trial targets tough stomach and pancreatic cancers
NCT ID NCT07394205
Summary
This is an early-stage study testing a new type of personalized immune cell therapy called CBG131 for adults with advanced stomach or pancreatic cancer that has a specific marker (CLDN18.2). The main goals are to find the safest and most effective dose and to see if the treatment can shrink tumors. All 18 participants will receive the therapy, which involves collecting their own immune cells, modifying them to fight cancer, and infusing them back after a short course of chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC AND PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.